Shares of Transenterix Inc (NYSEAMERICAN:TRXC) gapped up before the market opened on Monday . The stock had previously closed at $1.81, but opened at $1.86. Transenterix shares last traded at $2.00, with a volume of 3244600 shares traded.

Several analysts have recently issued reports on TRXC shares. Ladenburg Thalmann Financial Services set a $5.00 price target on shares of Transenterix and gave the stock a “buy” rating in a research report on Friday, October 20th. Stifel Nicolaus reissued a “buy” rating and set a $4.00 price target (up previously from $3.75) on shares of Transenterix in a research report on Monday, October 30th. BTIG Research reissued a “hold” rating on shares of Transenterix in a research report on Monday, December 18th. Finally, Zacks Investment Research cut shares of Transenterix from a “hold” rating to a “sell” rating in a research report on Thursday, January 11th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company’s stock. Transenterix has a consensus rating of “Hold” and an average target price of $2.61.

The stock has a market cap of $398.48, a P/E ratio of -3.18 and a beta of 2.02.

Transenterix (NYSEAMERICAN:TRXC) last announced its quarterly earnings results on Thursday, November 9th. The medical instruments supplier reported ($0.09) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.09). Transenterix had a negative net margin of 21,045.36% and a negative return on equity of 137.69%.

In other news, CFO Joseph P. Slattery sold 333,000 shares of the stock in a transaction that occurred on Tuesday, November 14th. The stock was sold at an average price of $2.93, for a total value of $975,690.00. Following the completion of the sale, the chief financial officer now directly owns 440,974 shares of the company’s stock, valued at $1,292,053.82. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Joseph P. Slattery sold 529,609 shares of the stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $2.80, for a total value of $1,482,905.20. Following the completion of the sale, the chief financial officer now directly owns 440,974 shares of the company’s stock, valued at $1,234,727.20. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Transenterix stock. Ladenburg Thalmann Financial Services Inc. increased its stake in shares of Transenterix Inc (NYSEAMERICAN:TRXC) by 87.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 79,150 shares of the medical instruments supplier’s stock after purchasing an additional 37,000 shares during the quarter. Ladenburg Thalmann Financial Services Inc. owned 0.05% of Transenterix worth $113,000 as of its most recent SEC filing.

ILLEGAL ACTIVITY WARNING: “Transenterix (TRXC) Shares Gap Up to $1.86” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this story can be read at https://www.thecerbatgem.com/2018/01/22/transenterix-trxc-shares-gap-up-to-1-86.html.

Transenterix Company Profile

TransEnterix, Inc is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company’s ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera.

Receive News & Ratings for Transenterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transenterix and related companies with MarketBeat.com's FREE daily email newsletter.